Abbott (ABT) Wins FDA and EU Approval for AI-Powered Stent Guidance Software

Abbott Laboratories (NYSE:ABT) announced on April 28, 2026, that the U.S. Food and Drug Administration (FDA) and European regulators have granted clearance and CE Mark approval, respectively, for its next-generation Ultreon 3.0 software. The software is an AI-powered coronary imaging platform designed to guide physicians during artery stent placement.

The Product

Ultreon 3.0 is an enhanced version of Abbott's existing Ultreon software, leveraging artificial intelligence to analyze optical coherence tomography (OCT) images and provide real-time guidance for stent placement. Key features include:

• Improved automatic detection of vessel boundaries
• Advanced plaque analysis
• Enhanced recommendations for stent size and positioning
• Seamless integration with Abbott's existing imaging systems

Pricing and Availability

Abbott has not disclosed pricing details, but the software is now available in the U.S. and European markets through the company's direct sales channels.

Competition

Abbott faces competition from companies like Boston Scientific and Medtronic, which also offer coronary imaging solutions. However, Ultreon 3.0's advanced AI capabilities may provide a competitive edge in improving patient outcomes and reducing complications.

Potential Impact on the Company

Ultreon 3.0 is expected to strengthen Abbott's position in the cardiovascular device market, which is experiencing growing demand. The software could help Abbott increase its market share in coronary stents, especially as hospitals increasingly adopt AI-powered technologies.